4,860 GRAIL, Inc. $GRAL Shares Sold by Profund Advisors LLC

Profund Advisors LLC decreased its holdings in GRAIL, Inc. (NASDAQ:GRAL) by 24.2% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 15,218 shares of the company’s stock after selling 4,860 shares during the period. Profund Advisors LLC’s holdings in GRAIL were worth $2,132,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Bank of America Corp DE increased its position in shares of GRAIL by 29.0% in the first quarter. Bank of America Corp DE now owns 914,114 shares of the company’s stock worth $47,241,000 after acquiring an additional 205,611 shares in the last quarter. Russell Investments Group Ltd. lifted its holdings in shares of GRAIL by 255.6% during the 2nd quarter. Russell Investments Group Ltd. now owns 28,403 shares of the company’s stock valued at $1,939,000 after acquiring an additional 20,416 shares in the last quarter. State Street Corp lifted its holdings in shares of GRAIL by 26.1% during the 2nd quarter. State Street Corp now owns 2,385,514 shares of the company’s stock valued at $162,859,000 after acquiring an additional 493,621 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of GRAIL during the 2nd quarter valued at $1,171,000. Finally, BlackRock Inc. boosted its position in GRAIL by 20.5% during the 2nd quarter. BlackRock Inc. now owns 3,577,075 shares of the company’s stock worth $244,207,000 after purchasing an additional 608,539 shares during the period.

Wall Street Analyst Weigh In

GRAL has been the subject of several recent research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of GRAIL in a report on Thursday, October 15th. Guggenheim upped their target price on GRAIL from $75.00 to $155.00 and gave the stock a “buy” rating in a research report on Thursday, October 1st. TD Cowen upped their target price on GRAIL from $88.00 to $180.00 and gave the stock a “buy” rating in a research report on Tuesday, October 13th. Morgan Stanley increased their target price on GRAIL from $60.00 to $120.00 and gave the company an “equal weight” rating in a research note on Monday, October 12th. Finally, Canaccord Genuity Group raised their target price on GRAIL from $80.00 to $150.00 and gave the company a “buy” rating in a report on Monday, September 28th. Five research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $119.80.

GRAIL Stock Performance

GRAL opened at $143.43 on Monday. GRAIL, Inc. has a twelve month low of $41.50 and a twelve month high of $166.48. The firm has a market cap of $6.41 billion, a price-to-earnings ratio of -14.71 and a beta of 2.86. The company has a fifty day simple moving average of $112.02 and a 200 day simple moving average of $78.55.

GRAIL (NASDAQ:GRAL) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($2.56) EPS for the quarter, topping analysts’ consensus estimates of ($2.66) by $0.10. GRAIL had a negative net margin of 236.95% and a negative return on equity of 15.88%. The firm had revenue of $44.69 million for the quarter, compared to analyst estimates of $42.39 million. On average, analysts forecast that GRAIL, Inc. will post -10.07 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Aaron Freidin sold 23,619 shares of the stock in a transaction dated Monday, October 5th. The stock was sold at an average price of $146.39, for a total value of $3,457,585.41. Following the completion of the transaction, the chief financial officer owned 225,364 shares of the company’s stock, valued at approximately $32,991,035.96. This represents a 9.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Joshua Ofman sold 61,452 shares of the firm’s stock in a transaction that occurred on Monday, September 21st. The shares were sold at an average price of $97.74, for a total value of $6,006,318.48. Following the sale, the chief executive officer owned 362,271 shares of the company’s stock, valued at approximately $35,408,367.54. This trade represents a 14.50% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 129,944 shares of company stock worth $14,832,805. 1.83% of the stock is currently owned by corporate insiders.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a healthcare company focused on developing blood-based screening technologies for the early detection of cancer. Its principal product is Galleri, a multi-cancer early detection test designed to identify DNA patterns associated with multiple types of cancer from a single blood sample.

Galleri is intended for use alongside recommended cancer screenings and is available by prescription through qualified healthcare providers in the United States. The test is offered as a laboratory-developed test and has not been approved or cleared by the U.S.